EGF and hepatocellular carcinoma: The EGF 61*A/G polymorphism was associated with increased risk of HCC among Caucasians (G-allele vs. A-allele, OR = 1.75, 95% CI = 1.03–2.97, P = 0.04; G/G vs. A/A, OR = 2.92, 95% CI = 1.06–8.06, P = 0.04; recessive model, OR = 2.80, 95% CI = 1.17–6.73, P = 0.02).